The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development
Open accessAbstract
Highlights ► Virus-like particles (VLPs) are a class of recombinant subunit vaccines. ► VLPs resemble native viruses but lack infectious genetic material. ► VLPs are promising vaccines due to strong immunogenicity and safety. ► VLPs can be produced in prokaryotic or eukaryotic expression systems, or in vitro. ► VLP-based vaccine candidates targeting many diseases are in clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
(2015) · Elsevier eBooks · doi:10.1016/c2012-1-00075-6 · Cited by 2,577
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C., & Walsh, E. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043951 · Cited by 2,226
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A.-B., Romanowski, B., Roteli-Martins, C. M., Jenkins, D., Schuind, A., Costa Clemens, S. A., & Dubin, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68439-0 · Cited by 1,632
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Cited by
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 555
Breaking Down the Barriers to Precision Cancer Nanomedicine
von Roemeling, C., Jiang, W., Chan, C. K., Weissman, I. L., & Kim, B. Y. S. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.07.006 · Cited by 330
Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery
Ho, W., Gao, M., Li, F., Li, Z., Zhang, X., & Xu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001812 · Cited by 261
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies
Cid, R., & Bolívar, J. (2021) · Biomolecules · doi:10.3390/biom11081072 · Cited by 176
Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine
Marsian, J., Fox, H., Bahar, M. W., Kotecha, A., Fry, E. E., Stuart, D. I., Macadam, A. J., Rowlands, D. J., & Lomonossoff, G. P. (2017) · Nature Communications · doi:10.1038/s41467-017-00090-w · Cited by 121
Metadata
- Authors
- Kushnir, N., Streatfield, S. J., & Yusibov, V.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 31
- Issue
- 1
- Pages
- 58-83
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2120321866
- Cited by
- 587
- References
- 239
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. https://app.cochat.ai/papers/10.1016/j.vaccine.2012.10.083
- The paper
- Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012). Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine. https://doi.org/10.1016/j.vaccine.2012.10.083
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
